Abstract: Described are improved systems, computer program products, and methods for providing an improved approach to implement dynamic cache management, where statistics are maintained for the use and reuse of resources by resource type. The statistics are used to determine which resource types to cache and which types should not be cached.

Abstract: The present disclosure provides biomarkers for the identification of prostate cancer and methods of use. The present disclosure also provide biomarkers that can be used for determining risk of developing prostate cancer, aggressiveness of prostate cancer and survival rate for subpopulations of African American males or non-Hispanic white males.

Abstract: The present disclosure provides biomarkers for the identification of prostate cancer and methods of use. The present disclosure also provide biomarkers that can be used for determining risk of developing prostate cancer, aggressiveness of prostate cancer and survival rate for subpopulations of African American males or non-Hispanic white males.

Abstract: Techniques related to cache recovery for failed database instances are disclosed. A first database instance and a second database instance share a primary persistent storage and a secondary persistent storage. Each database instance stores, in volatile memory, a respective primary cache of a respective set of data stored on the primary persistent storage. Each database instance also stores, in volatile memory, a respective set of header data. Further, each database instance moves the respective set of data from the respective primary cache to a respective secondary cache on the secondary persistent storage. Still further, each database instance stores, on the secondary persistent storage, a respective set of persistent metadata. When the first database instance becomes inoperative, the second database instance retrieves, from the secondary persistent storage, persistent metadata corresponding to data stored in a secondary cache of the first database instance.

Abstract: A sensor housing system is used to monitor the lifetime of a motor or other device. A protected housing shields a microprocessor and several sensors. The device communicates to a user information about the health of the motor or other device using thermal, vibrational, or other measurements. The information is compared to a baseline which provides a warning threshold. Once the threshold is passed, the microprocessor can alert the user that the motor or other device is about to fail.

Abstract: A method of classifying a patient for eligibility for cancer therapy based on the presence or absence of splicing variants in a sample of the patient's cancer tissue. Also, a method of screening cancer therapies for efficacy against splicing variants. More specifically, the methods relate to novel splicing variants of genes associated with cancer risk and survival, particularly splicing variants of PIK3CD, FGFR3, TSC2, RASGRP2, ITGA4, MET, NF1 and BAK1. Also more specifically, the methods relate to classifying a patient for eligibility for cancer therapy involving the use of GS-1101.

Abstract: Techniques related to cache recovery for failed database instances are disclosed. A first database instance and a second database instance share a primary persistent storage and a secondary persistent storage. Each database instance stores, in volatile memory, a respective primary cache of a respective set of data stored on the primary persistent storage. Each database instance also stores, in volatile memory, a respective set of header data. Further, each database instance moves the respective set of data from the respective primary cache to a respective secondary cache on the secondary persistent storage. Still further, each database instance stores, on the secondary persistent storage, a respective set of persistent metadata. When the first database instance becomes inoperative, the second database instance retrieves, from the secondary persistent storage, persistent metadata corresponding to data stored in a secondary cache of the first database instance.

Abstract: The present disclosure provides biomarkers for the identification of prostate cancer and methods of use. The present disclosure also provide biomarkers that can be used for determining risk of developing prostate cancer, aggressiveness of prostate cancer and survival rate for subpopulations of African American males or non-Hispanic white males.

Abstract: A sensor housing system is used to monitor the lifetime of a motor or other device. A protected housing shields a microprocessor and several sensors. The device communicates to a user information about the health of the motor or other device using thermal, vibrational, or other measurements. The information is compared to a baseline which provides a warning threshold. Once the threshold is passed, the microprocessor can alert the user that the motor or other device is about to fail.

Abstract: A method of classifying a patient for eligibility for cancer therapy based on the presence or absence of splicing variants in a sample of the patient's cancer tissue. Also, a method of screening cancer therapies for efficacy against splicing variants. More specifically, the methods relate to novel splicing variants of genes associated with cancer risk and survival, particularly splicing variants of PIK3CD, FGFR3, TSC2, RASGRP2, ITGA4, MET, NF1 and BAK1. Also more specifically, the methods relate to classifying a patient for eligibility for cancer therapy involving the use of GS-1101.

Abstract: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.

Abstract: Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases.